Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19036942 | 1.00 | ALDH1A1 (0.33) | ALDH1A1HIF1AL3MBTL1MAPT | |
| SCHEMBL16201903 | 1.00 | ALDH1A1 (0.33) | ALDH1A1HIF1AL3MBTL1MAPT | |
| SCHEMBL25222379 | 0.90 | L3MBTL1 (0.39) | ALDH1A1HIF1AL3MBTL1MAPT | |
| SCHEMBL18385939 | 0.90 | L3MBTL1 (0.39) | ALDH1A1HIF1AL3MBTL1MAPT | |
| SCHEMBL20381805 | 0.90 | L3MBTL1 (0.39) | ALDH1A1HIF1AL3MBTL1MAPT | |
| SCHEMBL18392791 | 0.90 | L3MBTL1 (0.39) | ALDH1A1HIF1AL3MBTL1MAPT | |
| SCHEMBL25585820 | 0.90 | L3MBTL1 (0.39) | ALDH1A1HIF1AL3MBTL1MAPT | |
| SCHEMBL17590126 | 0.82 | — | — | |
| SCHEMBL14882979 | 0.82 | — | — | |
| SCHEMBL18392810 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028649-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2018-02-01 | — | — | US | disclosed |
| US-9480740-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2016-11-01 | — | — | US | disclosed |
| US-20140322268-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322268-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | ALDH1A1 3976/4885HIF1A 3973/4885L3MBTL1 164/4885 |
| US-20180028649-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | ALDH1A1 3967/4885HIF1A 3983/4885L3MBTL1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.